相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Iron and inflammation: in vivo and post-mortem studies in Parkinson's disease
Antonio Martin-Bastida et al.
JOURNAL OF NEURAL TRANSMISSION (2021)
Increased microglial activation in patients with Parkinson disease using [18F]-DPA714 TSPO PET imaging
Sonia Lavisse et al.
PARKINSONISM & RELATED DISORDERS (2021)
CN128: A New Orally Active Hydroxypyridinone Iron Chelator
Wenteng Chen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Effectiveness of the Iron Chelator CN128 in Mitigating the Formation of Dopamine Oxidation Products Associated with the Progression of Parkinson's Disease
Yingying Sun et al.
ACS CHEMICAL NEUROSCIENCE (2020)
Ferroptosis Mechanisms Involved in Neurodegenerative Diseases
Cadiele Oliana Reichert et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
X1INH, an improved next-generation affinity-optimized hydrazonic ligand, attenuates abnormal copper(I)/copper(II)-α-Syn interactions and affects protein aggregation in a cellular model of synucleinopathy
Daphne S. Cukierman et al.
DALTON TRANSACTIONS (2020)
Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system
Antonio Martin-Bastida et al.
BRAIN (2019)
Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in vivo 11C-BU99008 PET study
Heather Wilson et al.
BRAIN (2019)
Current Drugs and Potential Future Neuroprotective Compounds for Parkinson's Disease
Ivan Carrera et al.
CURRENT NEUROPHARMACOLOGY (2019)
The Efficacy of Iron Chelators for Removing Iron from Specific Brain Regions and the Pituitary-Ironing out the Brain
Robert R. Crichton et al.
PHARMACEUTICALS (2019)
The imidazoline I2 receptor agonist 2-BFI attenuates hypersensitivity and spinal neuroinflammation in a rat model of neuropathic pain
Justin N. Siemian et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Beneficial Effects of Flavonoids Against Parkinson's Disease
Un Ju Jung et al.
JOURNAL OF MEDICINAL FOOD (2018)
Evaluation of 11C-BU99008, a PET Ligand for the Imidazoline2 Binding Site in Human Brain
Robin J. Tyacke et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Beneficial Effects of Green Tea Catechins on Neurodegenerative Diseases
Monira Pervin et al.
MOLECULES (2018)
New Progress on the Role of Glia in Iron Metabolism and Iron-Induced Degeneration of Dopamine Neurons in Parkinson's Disease
Huamin Xu et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2018)
Motor associations of iron accumulation in deep grey matter nuclei in Parkinson's disease: a cross-sectional study of iron-related magnetic resonance imaging susceptibility
A. Martin-Bastida et al.
EUROPEAN JOURNAL OF NEUROLOGY (2017)
Overview of quantitative susceptibility mapping
Andreas Deistung et al.
NMR IN BIOMEDICINE (2017)
Safety profiles of iron chelators in young patients with haemoglobinopathies
Sebastian Botzenhardt et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2017)
Recent advances in discovery and development of natural products as source for anti-Parkinson's disease lead compounds
Hongjia Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Neuromelanin in parkinsonian disorders: an update
Antonio Martin-Bastida et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2017)
Neurotoxic reactive astrocytes are induced by activated microglia
Shane A. Liddelow et al.
NATURE (2017)
Ferroptosis and cell death mechanisms in Parkinson's disease
Stephanie J. Guiney et al.
NEUROCHEMISTRY INTERNATIONAL (2017)
Astrocyte hepcidin is a key factor in LPS-induced neuronal apoptosis
Lin-Hao You et al.
CELL DEATH & DISEASE (2017)
The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease
David I. Finkelstein et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2017)
Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease
Antonio Martin-Bastida et al.
SCIENTIFIC REPORTS (2017)
Biomonitorization of iron accumulation in the substantia nigra from Lewy body disease patients
Belen Fernandez et al.
TOXICOLOGY REPORTS (2017)
Neuroprotective and neurorestorative potential of propargylamine derivatives in ageing: focus on mitochondrial targets
Orit Bar-Am et al.
JOURNAL OF NEURAL TRANSMISSION (2016)
Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics
Abdel A. Belaidi et al.
JOURNAL OF NEUROCHEMISTRY (2016)
Meta-analysis of brain iron levels of Parkinson's disease patients determined by postmortem and MRI measurements
Jian-Yong Wang et al.
SCIENTIFIC REPORTS (2016)
Quantifying brain iron deposition in patients with Parkinson's disease using quantitative susceptibility mapping, R2 and R2
Jeam Haroldo Oliveira Barbosa et al.
MAGNETIC RESONANCE IMAGING (2015)
Automated Neuromelanin Imaging as a Diagnostic Biomarker for Parkinson's Disease
Gabriel Castellanos et al.
MOVEMENT DISORDERS (2015)
Brain-gut-microbiota axis in Parkinson's disease
Agata Mulak et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease
David Devos et al.
ANTIOXIDANTS & REDOX SIGNALING (2014)
Desferrithiocin: A Search for Clinically Effective Iron Chelators
Raymond J. Bergeron et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
The role of iron in brain ageing and neurodegenerative disorders
Roberta Ward et al.
LANCET NEUROLOGY (2014)
Review: Iron metabolism and the role of iron in neurodegenerative disorders
M. Hadzhieva et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2014)
Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients
Karlijn J. Doorn et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2014)
Pro-inflammatory cytokines modulate iron regulatory protein 1 expression and iron transportation through reactive oxygen/nitrogen species production in ventral mesencephalic neurons
Jia Wang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2013)
Iron uptake in quiescent and inflammation-activated astrocytes: A potentially neuroprotective control of iron burden
Ilaria Pelizzoni et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2013)
Higher iron in the red nucleus marks Parkinson's dyskinesia
Mechelle M. Lewis et al.
NEUROBIOLOGY OF AGING (2013)
Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease
Moussa B.H. Youdim et al.
PARKINSONISM & RELATED DISORDERS (2013)
Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy
Alessia Pepe et al.
JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE (2013)
An 18-kDa Translocator Protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28
David R. Owen et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2012)
Evaluation and initial in vitro and ex vivo characterization of the potential positron emission tomography ligand, BU99008 (2-(4,5-Dihydro-1H-imidazol-2-yl)-1-methyl-1H-indole), for the imidazoline2 binding site
Robin J. Tyacke et al.
SYNAPSE (2012)
T1-Weighted MRI Shows Stage-Dependent Substantia Nigra Signal Loss in Parkinson's Disease
Stefan T. Schwarz et al.
MOVEMENT DISORDERS (2011)
Neuromelanin Activates Microglia and Induces Degeneration of Dopaminergic Neurons: Implications for Progression of Parkinson's Disease
Wei Zhang et al.
NEUROTOXICITY RESEARCH (2011)
Accumulation of Non-Transferrin-Bound Iron by Neurons, Astrocytes, and Microglia
Glenda M. Bishop et al.
NEUROTOXICITY RESEARCH (2011)
Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: nested case-control study
Jane A. Driver et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Mechanisms Underlying Inflammation in Neurodegeneration
Christopher K. Glass et al.
CELL (2010)
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias
Maria Domenica Cappellini et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Minocycline 1-Year Therapy in Multiple-System-Atrophy: Effect on Clinical Symptoms and [11C] (R)-PK11195 PET (MEMSA-Trial)
Richard Dodel et al.
MOVEMENT DISORDERS (2010)
Anti-inflammatory drugs and risk of Parkinson disease A meta-analysis
Joshua J. Gagne et al.
NEUROLOGY (2010)
[C-11]-PK11195 PET: Quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease?
A. L. Bartels et al.
PARKINSONISM & RELATED DISORDERS (2010)
A Nurr1/CoREST Pathway in Microglia and Astrocytes Protects Dopaminergic Neurons from Inflammation-Induced Death
Kaoru Saijo et al.
CELL (2009)
Medicinal Inorganic Chemistry Approaches to Passivation and Removal of Aberrant Metal Ions in Disease
Lauren E. Scott et al.
CHEMICAL REVIEWS (2009)
Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia
Shahina Daar et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Mutant α-Synuclein Overexpression Mediates Early Proinflammatory Activity
Xiaomin Su et al.
NEUROTOXICITY RESEARCH (2009)
Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease
Luigi Zecca et al.
ACTA NEUROPATHOLOGICA (2008)
Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease
Luigi Zecca et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Midbrain iron content in early Parkinson disease - A potential biomarker of disease status
W. R. Wayne Martin et al.
NEUROLOGY (2008)
Monoamine neurons in the human brain stem: anatomy, magnetic resonance imaging findings, and clinical implications
Makoto Sasaki et al.
NEUROREPORT (2008)
Translocator protein 18 kDa (TSPO): Molecular sensor of brain injury and repair
Ming-Kai Chen et al.
PHARMACOLOGY & THERAPEUTICS (2008)
The pivotal role of astrocytes in the metabolism of iron in the brain
Ralf Dringen et al.
NEUROCHEMICAL RESEARCH (2007)
Selective iron chelation in Friedreich ataxia:: biologic and clinical implications
Nathalie Boddaert et al.
BLOOD (2007)
Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: A case-control study
J. H. Bower et al.
NEUROLOGY (2006)
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia
MD Cappellini et al.
BLOOD (2006)
Transport kinetics of iron chelators and their chelates in Caco-2 cells
XP Huang et al.
PHARMACEUTICAL RESEARCH (2006)
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
A Gerhard et al.
NEUROBIOLOGY OF DISEASE (2006)
Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease
HL Chen et al.
ANNALS OF NEUROLOGY (2005)
Microglial activation and dopamine terminal loss in early Parkinson's disease
Y Ouchi et al.
ANNALS OF NEUROLOGY (2005)
Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition
Emilie Croisier et al.
JOURNAL OF NEUROINFLAMMATION (2005)
Imaging iron stores in the brain using magnetic resonance imaging
EM Haacke et al.
MAGNETIC RESONANCE IMAGING (2005)
Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases
O Weinreb et al.
JOURNAL OF NUTRITIONAL BIOCHEMISTRY (2004)
Susceptibility weighted imaging (SWI)
EM Haacke et al.
MAGNETIC RESONANCE IN MEDICINE (2004)
The neuromelanin of human substantia nigra: Physiological and pathogenic aspects
FA Zucca et al.
PIGMENT CELL RESEARCH (2004)
Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease
HL Chen et al.
ARCHIVES OF NEUROLOGY (2003)
Iron-binding characteristics of neuromelanin of the human substantia nigra
KL Double et al.
BIOCHEMICAL PHARMACOLOGY (2003)
Development of tridentate iron chelators: From desferrithiocin to ICL670
H Nick et al.
CURRENT MEDICINAL CHEMISTRY (2003)
Magnetic resonance imaging of brain iron
JF Schenck
JOURNAL OF THE NEUROLOGICAL SCIENCES (2003)
Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia
LJ Anderson et al.
LANCET (2002)
Pharmacological inhibitors of MAPK pathways
JM English et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2002)
Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and-2
C Knott et al.
MOLECULAR AND CELLULAR NEUROSCIENCE (2000)
Survival in β-thalassaemia major in the UK:: data from the UK thalassaemia register
B Modell et al.
LANCET (2000)
分享论文
